Enliven Therapeutics Inc. is a clinical-stage precision oncology company focused on the discovery and development of small molecule kinase inhibitors. The Company's lead product candidate includes ELVN-001 and ELVN-002. Enliven Therapeutics Inc., formerly known as Imara Inc., is based in Boulder, CO.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-89.02M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.02 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -31.84% |
| Return on Assets (Trailing 12 Months) | -30.09% |
| Current Ratio (Most Recent Fiscal Quarter) | 21.07 |
| Quick Ratio (Most Recent Fiscal Quarter) | 21.06 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $5.88 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.57 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.89 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.92 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 49.07M |
| Free Float | 34.74M |
| Market Capitalization | $870.49M |
| Average Volume (Last 20 Days) | 0.35M |
| Beta (Past 60 Months) | 1.07 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 29.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 95.08% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |